Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) have received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $34.00.
TVTX has been the subject of a number of research analyst reports. SVB Leerink reduced their price target on shares of Travere Therapeutics from $45.00 to $38.00 and set an “outperform” rating for the company in a research report on Thursday, October 20th. Bryan, Garnier & Co began coverage on Travere Therapeutics in a report on Wednesday, September 21st. They issued a “sell” rating and a $17.00 price objective on the stock. Evercore ISI lowered their price target on Travere Therapeutics to $30.00 in a report on Thursday, October 20th. HC Wainwright lowered their price target on Travere Therapeutics from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Friday, October 14th. Finally, Piper Sandler lowered their price target on Travere Therapeutics from $39.00 to $38.00 and set an “overweight” rating on the stock in a report on Thursday, October 13th.
Travere Therapeutics Price Performance
TVTX stock opened at $21.51 on Wednesday. The company has a current ratio of 4.08, a quick ratio of 4.03 and a debt-to-equity ratio of 3.73. Travere Therapeutics has a one year low of $20.20 and a one year high of $31.65. The firm has a market capitalization of $1.38 billion, a PE ratio of -5.15 and a beta of 0.52. The firm has a 50-day moving average of $23.86 and a two-hundred day moving average of $24.46.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of TVTX. US Bancorp DE lifted its holdings in shares of Travere Therapeutics by 1,372.3% during the first quarter. US Bancorp DE now owns 1,487 shares of the company’s stock valued at $38,000 after acquiring an additional 1,386 shares during the period. Point72 Hong Kong Ltd lifted its holdings in shares of Travere Therapeutics by 2,540.3% during the first quarter. Point72 Hong Kong Ltd now owns 5,439 shares of the company’s stock valued at $140,000 after acquiring an additional 5,233 shares during the period. Quantbot Technologies LP bought a new position in shares of Travere Therapeutics during the second quarter valued at $157,000. E Fund Management Co. Ltd. bought a new position in shares of Travere Therapeutics during the first quarter valued at $205,000. Finally, Intrust Bank NA bought a new position in shares of Travere Therapeutics during the second quarter valued at $206,000.
Travere Therapeutics Company Profile
Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.
- Get a free copy of the StockNews.com research report on Travere Therapeutics (TVTX)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.